Who is sponsoring NCT02730104?

NCT02730104 is sponsored by Ipsen.

What condition does NCT02730104 study?

NCT02730104 studies Gastroenteropancreatic Neuroendocrine Tumors.

Is NCT02730104 still recruiting?

NCT02730104 is currently completed. Last updated 26 June 2020.

Last reviewed 2020-06-26 · How we verify

NCT02730104

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Community-based Neuroendocrine Tumor (NET) Research Study

Completed Last updated 26 June 2020

What this trial tests

trial in Gastroenteropancreatic Neuroendocrine Tumors in 100 participants. Completed in 13 May 2020.

Timeline

23 November 2015

Primary endpoint
13 May 2020

13 May 2020

Quick facts

Lead sponsor	Ipsen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	23 November 2015
Primary completion	13 May 2020
Estimated completion	13 May 2020
Sites	12 locations across United States

Conditions studied

Gastroenteropancreatic Neuroendocrine Tumors — all drugs for Gastroenteropancreatic Neuroendocrine Tumors →

Sponsor

Ipsen — full company profile →

Who can join

18 and older, any sex, with Gastroenteropancreatic Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.
Colao A, de Nigris F, Modica R, Napoli C. · · 2020 · cited 31× · PMID 33384663 · DOI 10.3389/fendo.2020.604341
An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis.
Yan H, Zhang JL, Leung KT, Lo KW, et al · · 2023 · cited 8× · PMID 36765694 · DOI 10.3390/cancers15030736
Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
Paulson S, Ray D, Aranha S, Scales A, et al · · 2022 · cited 6× · PMID 36136274 · DOI 10.1007/s40487-022-00208-1

Verify or expand the search:

Other recruiting trials for Gastroenteropancreatic Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07165886 — Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastr · Phase 2, PHASE3 · recruiting
NCT04711135 — Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs · Phase 2 · active not recruiting

Other Ipsen trials

Trials by the same sponsor.

NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02730104 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ipsen
Last refreshed: 26 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02730104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing